Therapeutic Inhibitory Activities of N‐Hydroxy Derived Cytidines: A Patent Overview

Abstract

The structural enantiomers of nucleoside analogs are cytidine and β‐D‐N4‐hydroxycytidine derivatives. This implies their significance as excellent anticancer agents by their compatibility with DNA/RNA polymerases and antiviral agents in particular, as polymerase inhibitors by with their ability to selectively inhibit against the Human Corona Virus and Severe acute respiratory syndrome coronavirus (SARS‐CoV) by reduction assay. This encouraged us to explore and collect the available data on the subject of therapeutic significance of cytidines and β‐D‐N4‐hydroxycytidines. Many of their pharmacologically significant derivatives can serve as alternate targets to be investigated for various therapeutic applications. However, only a few cytidine and β‐D‐N4‐hydroxycytidine derivatives were patented in the past decade. The Half maximal inhibitory concentration (IC50) values of these patented therapeutic inhibitors range between 0.003 to<50 μM, depending on the nature of the biological assays. The current review examines cytidine and β‐D‐N4‐hydroxycytidine derivatives as anticancer and antiviral targets, to explore over their developments with reference to the advancement of biological, pharmacological and therapeutic activates reported in patents over the last decade. Using various databases of Justia patent, Lens database and Google patents, the granted patents from 2010 to 2020 were retrieved. It is revealed that, the discovery of cytidine scaffolds were encouraged and disclosed for further improvements as therapeutical targets. Further the increase in the number of scientific reports and publications covering anticancer and antiviral agents for selective treatment of different cancers and viral infections indicate the significance of this subject along with few limitations that seek investigations in terms of optimistic, and interactive biological effects.

New analytical method development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method

“…The molecular formula of Molnupiravir C13H19N3O7 and has a molecular weight of 329.309 gm/mole. It is a white crystalline solid soluble in water, freely soluble in methanol, ethanol and DMSO [5][6][7].…”